Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te

Fresenius Medical Care Confirms Outlook for

Reports Strong Second Quarter and Half Year Results

Bad Homburg, Germany Fresenius Medical Care

AG & Co. KGaA ( the Company ), the world s largest provider

of Dialysis Products and Services, today announced its results for the second

quarter and first half of 2008.

Second Quarter 2008:

Net revenue for the second quarter of 2008 increased by 11%

to $2,665 million (7% at constant currency) compared to the second quarter

of 2007.Organic revenue growth worldwide

was 7%. Dialysis Services revenue grew by 7% to $1,924 million (5% at

constant currency) in the second quarter of 2008. Dialysis Product revenue

increased by 22% to $741 million (12% at constant currency) in the same

North America revenue increased by 3% to $1,715 million. Organic

revenue growth was 4%. Dialysis Services revenue grew by 2% to $1,533 million.

Excluding the effects of the divestiture of the perfusion business in spring

2007, Dialysis Services revenue increased by 3%. Average revenue per

treatment for the U.S. clinics was unchanged at $327 in the second quarter of 2008

compared to $327 for the same quarter in 2007 and $326 for the first quarter of

2008. The sequential improvement in the revenue per treatment during the second

quarter of 2008 compared to the first quarter of 2008 was due to an increase in

EPO utilization. The Average Selling Price (ASP) for EPO in the second quarter

of 2008 remained approximately 5% less than second quarter of 2007 pricing.Dialysis

Product revenue increased by 13% to $182 million. This performance was led

by strong sales among the whole product portfolio including the phosphate

binding drug PhosLo .

International revenue was $950 million, an increase of 28% (14% at

constant currency) compared to the second quarter of 2007. Organic revenue

growth in the International segment was 14%. Dialysis Services revenue reached $391

million, an increase of 32% (19% at constant currency). Dialysis Product revenue

rose 25% to $559 million (11% at constant currency), led by strong

dialyzer and dialysis machine sales.

income (EBIT) increased

by 10% to $429 million

compared to $391 million in the second quarter of 2007 resulting in an operating

margin of 16.1% compared to 16.3% for the second quarter 2007. This margin

decrease mainly reflected the increased expenditures for our research and

development activities. The strong underlying business was supported by

increased reimbursement rates, dialysis services cost containment and a

continued strong performance of renal products including PhosLo .

This was partially offset by a reduction in reimbursement and a lower

utilization of EPO as well as start-up of new clinics and increased costs for the

anticoagulant drug Heparin due to suspension of production by the principal

Net interest expense for the second quarter of 2008 was

$82 million compared to $92 million in the same quarter of 2007. This positive

development was mainly attributable to lower average interest rates associated

with changes in the financing structure due to the redemption of a portion of

the Trust Preferred Securities.

Income tax expense was $129 million for the second quarter of 2008 compared to $113 million

in the second quarter of 2007, reflecting effective tax rates of 37.2% and 38.0%, respectively.

Net income for the second quarter 2008 was $211 million,

Earnings per share (EPS) for the second quarter of 2008 rose 18% to $0.71 per ordinary share compared

to $0.60 for the second quarter of 2007. Earnings per ordinary American

Depository Share (ADS) are equivalent as one ADS represents one share as a

result of the change in ratio of the Company s ordinary shares and preference shares

to ADSs. The weighted average number of shares outstanding for the second quarter

of 2008 was approximately 296.7 million shares compared to 295.4 million

shares for the second quarter of 2007. The increase in shares outstanding is

due to stock option exercises in 2007 and also in the first half of 2008.

In the second quarter of 2008,

the Company generated $209 million in cash

representing 8% of revenue. The cash flow generation was impacted by increases

in inventory and other working capital.

A total of $179 million was

spent for capital expenditures, net of disposals. Free Cash

Flow before acquisitions was $30 million compared to $95 million

in the second quarter of 2007. A total of $58 million in

cash was used for acquisitions, net of divestitures.

Revenue and Earnings

revenue was $5,177 million, up 10% from the

first half of 2007. At constant currency, net revenue rose 6%. Organic growth

was 6% in the first six months of 2008.

income (EBIT) increased

by 8% to $818 million compared to $756 million in the

first half of 2007, resulting in an operating margin of 15.8% compared to 16.0%

for the first half of 2007. This development mainly reflected higher research

and development expenses. Reduced reimbursement rates for EPO and lower

utilization of EPO as well as start-up cost for new clinics were offset by

increases in underlying reimbursement rates, cost containment and contributions

interest expense for the first six months of 2008

was $165 million compared to $187

million in the same period of 2007. The reduction was mainly due to lower

average interest rates associated with changes in our financing structure.

Income tax expense was $243 million in the first half of 2008 compared

to $216 million in the same period in 2007, reflecting tax rates of 37.2% and 38.0%, respectively.

For the first half of 2008, net income was $397 million, up 17% from

the first half of 2007.

In the first six months of

2008, Earnings per ordinary share

rose 17% to $1.34. The weighted average number of shares outstanding during the

first half of 2008 was approximately 296.6 million.

from operations during the first six months of

2008 was $401 million compared to $508 million for the same period in

2007. Cash Flow generation was impacted by higher DSO and increased inventory partially

offset by increased earnings.

A total of $332 million

was used for capital expenditures,